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Abstract 
Purpose: To investigate the effect of pegylated niosomal vincristine (VCR) on enhanced performance, 
drug resistance and prolonged blood circulation time. 
Methods: Pegylated niosomal VCR was synthesized by reverse phase evaporation. The mean 
diameter, size distribution, and zeta potential of pegylated niosomal VCR were evaluated using a 
Zetasizer. The half-maximal concentration (IC50) values of pegylated niosomal VCR and standard VCR 
were determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The 
impact of pegylated niosomal VCR on apoptosis and cell cycle of BCL1 lymphoma cancer cells were 
investigated. 
Results: The mean diameter, size distribution and zeta potential of pegylated niosomal VCR were 220 
nm, 0.4, and –18.8 mV, respectively. Cell proliferation was evaluated using the MTT assay. The IC50 
values of pegylated niosomal VCR and standard VCR were 1.6 and 3.5 μg/mL, respectively, after a 24-
h incubation. The cytotoxicity of pegylated niosomal VCR was twice that of standard VCR. Furthermore, 
flow cytometric analysis of the cell cycle showed that pegylated niosomal VCR induced greater mitotic 
arrest than did standard VCR. 
Conclusions: The findings demonstrate the effective antitumor activity of pegylated niosomal VCR 
compared with standard VCR. 
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Vincristine sulfate (VCR) is a water-soluble 
alkaloid that can be extracted from Catharanthus 
roseus [1]. Clinically, VCR is used to treat 
various cancers, including lymphoma. The 
molecular mechanism of the drug involves 
inhibition of microtubules, leading to inhibition of 
cell division during metaphase of mitosis [2]. 
However, along with its anticancer activity, VCR 
has severe side effects, such as neurotoxicity 
and peripheral sensorimotor neuropathy. 
Multidrug resistance has limited its clinical 
application. Indeed, the neuronal tubulin binding 
of VCR disrupts axonal microtubules, which can 
lead to autonomic and peripheral sensorimotor 
neuropathy [3]. 
 
To decrease the side effects and simultaneously 
increase the therapeutic activity of VCR, studies 
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have attempted to develop efficient drug delivery 
systems [4]. One effective strategy to achieve 
localized drug action is to entrap drugs in 
nanoparticles, since their small size results in 
enhanced drug performance and circumvents 
drug resistance [5]. Moreover, nanoparticle 
biodegradability leads to sustained release of 
drugs at the target site for days or weeks [6]. 
Various nanoparticle drug delivery systems have 
been reported for VCR [7]. 
 
Niosomes are vesicles consisting of cholesterol 
and nonionic surfactants [8] that can be used to 
entrap lipophilic and amphiphilic drugs [9]. 
Polyethylene glycol (PEG) is generally used for 
steric stabilization of nanocarrier-based drug 
delivery systems. It is a biocompatible, non-toxic, 
non-immunogenic polymer used to modulate the 
stability, solubility, plasma half-life, and clearance 
of different compounds. PEG can reduce carrier 
uptake by the reticular endothelial system, which 
prolongs the blood circulation time [10]. 
 
In this study, VCR was encapsulated in 
pegylated-niosomal nanoparticles using a 
reverse phase evaporation method. The 
nanoparticles were characterized in terms of 
size, size distribution, zeta potential, drug loading 
and encapsulation efficiencies, morphology, 
stability, and drug release. Finally, the efficacy of 
the nano-drug was evaluated according to cell 
cycle arrest [11] and apoptosis of the BCL1 cell 
line in vitro using the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay 






Fetal bovine serum (FBS), RPMI 1640 medium 
supplemented with glutaMAX, minimum essential 
medium containing glutamine and 
trypsin/ethylenediamine tetraacetic acid (1× 
solution), and penicillin/streptomycin solution 
were obtained from Gibco-BRL. The BCL1 
murine lymphoma cell line was supplied by the 
National Cell Bank, Pasteur Institute of Iran. 
Polyethylene glycol 3000 (PEG 3000), MTT 
solution, Span 60, and vincristine were procured 
from Sigma-Aldrich USA. Ethanol and 
isopropanol were purchased from Merck, 
Germany. All other reagents used were of 
analytical grade. 
 
Preparation of pegylated niosomal VCR 
 
Niosomes were prepared by a reverse phase 
evaporation method. Briefly, Span 60, 
cholesterol, PEG 3000, and VCR (7:3:1:1 molar 
ratio) were dissolved in 15 mL 96 % ethanol and 
stirred for 45 min at 300 rpm and room 
temperature. The solvent was evaporated on a 
rotary evaporator (Heidolph, Germany) at 90 rpm 
and 45 °C in a vacuum. The pegylated niosomal 
vesicles were formed after introducing normal 
saline (10 mL). The final concentrations of Span 
60, cholesterol, PEG 3000 and VCR were 12.5, 
5.3, 0.9, and 0.9 mM, respectively. The 
formulation was sonicated at 60 Hz in a bath 
sonicator (Bandelin Sonorex Digitec) for 10 min. 
Pegylated nanoparticles devoid of drug were 
prepared using this method. 
 
Characterization of nanoparticles 
 
The mean size, size distribution, zeta potential, 
shape, and probable crystallization of the 
pegylated nano-niosomal particles and pegylated 
nano-niosomal particles devoid of VCR were 
evaluated using the Zetasizer Nano Zen 3600 
(Malvern Instruments, UK) and electron 
microscope (Nikon, Tokyo, Japan). The 
morphologies of both lyophilized nanoparticles 
were assessed by scanning electron microscopy 
(SEM). To assess the entrapment efficiency, the 
unentrapped drug was removed by gel filtration 
from pegylated niosomal VCR through a 
Sephadex G-10 column and eluted with 
phosphate-buffered saline (PBS; pH 7.4). 
Subsequently, the vesicles were disrupted 
thoroughly using 0.1 % Triton X-100 and 
analyzed spectrophotometrically (UV-1601 PC, 
Shimadzu) at λ = 297 nm. Encapsulation 
efficiency (EE%) was calculated using Eq 1. 
  
EE (%) = {(Dt – D)/Dt}100 ………………. (1) 
 
where Dt is the total amount of drug used to 
prepare the nanoparticles, and D is the amount 
of unentrapped drug 
  
In vitro release study 
 
The rate of vincristine release from pegylated 
nano-niosomes was determined using a 
membrane diffusion technique. For this purpose, 
a pegylated niosomal VCR suspension was 
centrifuged (14,000 rpm, 4 °C, for 1 h) to remove 
the unentrapped drug in the supernatant. Then, 
the pellet was resuspended in PBS (pH 7.4). The 
vesicle suspension was added to dialysis tubing 
(10,000 Da cutoff, Sigma-Aldrich) and immersed 
in 50 mL PBS (pH 7.4, 37 °C) with constant 
shaking (150 rpm) using a magnetic stirrer. At 
different time intervals, the drug content of the 
buffer was analyzed at λ = 297 nm, and the 
percentage of drug release was determined with 
respect to the total amount of drug entrapped 
using a standard curve. 
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Evaluation of cytotoxic activity 
 
The cytotoxic effects of standard and pegylated 
niosomal VCR were evaluated by MTT assay. 
The BCL1 cells were cultured in 96-well plates 
(1×104/well) and incubated under 5 % CO2 at 37 
°C in RPMI 1640 medium containing 10 % FBS 
and 1 % penicillin/streptomycin for 24 h to 
promote their adhesion to the bottom of the plate. 
Then, the culture medium was replaced with 
medium containing standard VCR, pegylated 
niosomal VCR, or blank niosomal nanoparticles 
and then incubated for 24 or 48 h. After 
incubation, the formulations were replaced with 
tetrazolium salt (MTT solution) dissolved in PBS 
(0.5 mg/mL PBS) for 3 h. The MTT solution was 
then removed, and the formazan crystals that 
had deposited after oxidation were dissolved in 
isopropanol. The solubilized formazan was 
quantified using a conventional ELISA plate 
reader (BioTek Instruments  , VT, USA) at λ = 
540 nm. The IC50 was determined using Pharm-
PCS software. 
 
Cell cycle analysis  
 
Cells were seeded at a density of 1.0 × 106/well 
in six-well plates and cultured in RPMI 1640 
medium, as described above. After 24 h, the 
medium was replaced with medium containing 
standard or entrapped VCR, and the cells were 
incubated for 24 h. Subsequently, the cells were 
collected, washed, suspended in cold 1× PBS, 
fixed in 75 % ethanol, and stained with propidium 
iodide. The cell cycle distribution was then 
determined using the BD FACSCalibur flow 
cytometer. FCS Express ver. 3.0 software was 




Data are presented as mean ± standard 
deviation (SD) and were analyzed by SPSS ver. 




Characteristics of the nanoparticles 
 
The mean diameter, size distribution, and zeta 
potential of pegylated niosomal VCR were 
estimated to be 220 nm, 0.4, and −18.8 mV, 
respectively. Light microscopy demonstrated that 
the nanoparticles were in the form of unilamellar 
vesicles (ULVs), with spherical to ellipsoid hollow 
forms dispersed throughout the matrix (Figure 1). 
Crystallization was not apparent in the 
nanoparticles. The SEM results confirmed the 
preparation of nanoparticles with smooth 
spherical surfaces (Figure 1). The EE of the 




Figure 1: SEM micrograph of pegylated niosomal 
VCR nanoparticles (magnification: 2000×) 
 
In vitro drug release 
 
Pegylated niosomal VCR showed a drug release 
burst during the first 3 h, during which 21 % of 
the total release occurred (Figure 2). This was 
followed by sustained drug release until the end 
of the investigation. The amount of encapsulated 
VCR in pegylated niosomal nanoparticles 




Figure 2: Profile of the release of pegylated niosomal 
VCR in PBS buffer from niosomal VCR, shown as a 
percentage, at different times. A drug release burst 
occurred during the first 3 h. Values are the average of 
three independent experiments + 5% error. 
 
In vitro cytotoxicity 
 
The antitumor activity of standard VCR and 
pegylated niosomal VCR was evaluated by MTT 
assay using the BCL-1 murine lymphoma cell 
line. The cytotoxicities of standard VCR and 
pegylated niosomal VCR were evaluated after 24 
and 48 h and found to be independent of the 
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dose. However, the cytotoxic effect was more 
remarkable when the drug was associated with 
nanoparticles. The IC50 values for standard and 
pegylated niosomal VCR were 3.5 and 1.6 μg/mL 
after 24 h, respectively, and these values 
decreased to 2.8 and 1.2 μg/mL after 48 h, 
respectively. 
 
Encapsulated VCR stability 
 
The physical characteristics of pegylated 
niosomal VCR did not change significantly after 
storage at 4 °C for 4 months. The particle size 
increased from 220 nm to 255 nm after storage. 
The zeta potential of the pegylated niosomal 
VCR decreased after storage, from 18.8 to 13.6. 
 
Cell cycle  
 
VCR depolymerizes tubulin, causing G2/M 
arrest. Flow cytometric analysis showed an 
increase in the proportion of cells arrested in 
G2/M after treatment with pegylated niosomal 
VCR compared with standard VCR after 24 h. 
The pegylated niosomal VCR was more efficient 




A novel formulation for delivery of greater 
amounts of VCR was developed as an 
alternative to standard VCR, which has several 
side effects, including peripheral neuropathy and 
temporary blindness [12]. The results showed 
that reverse phase evaporation is suitable for 
preparing pegylated niosomal VCR nanoparticles 
[13], considering the high VCR entrapment 
efficiency. This process used lipophilic non-ionic 
surfactant (Span 60) and cholesterol to form 
spherical vesicles. PEG 3000 was introduced to 
produce PEG-coated niosomes to prolong their 
blood circulation time. PEG can inhibit niosome 
opsonization by preventing RES uptake [14]. The 
size, size distribution, and zeta potential of the 
nanoparticles were satisfactory. The size 
distribution value of 0.4 indicated that the 
nanocarriers containing VCR were relatively 
homogenous [15]. The zeta potential of 
pegylated niosomal VCR was 18.8 mV, indicating 
the stability of the particles. Light microscopy 
suggested that the ULVs resulted from 
sonication. Similarly, SEM indicated that the 
prepared nanoparticles were spherical with 
smooth surfaces. The cytotoxicity analyses 
revealed localization of the nanoparticles at the 
cell cytoplasm and a higher intracellular 
concentration of pegylated niosomal VCR 







Figure 3: Changes in the BCL-1 cell cycle distribution 
induced by VCR. BCL-1 cells were treated with 
standard or pegylated niosomal VCR for 24 h, and the 
cell cycle was analyzed by flow cytometry. 
Representative figures show the percentages of cells 
in each phase of the cell cycle 
 
 
The burst release of VCR occurred during the 
first 3 h. The observed burst release during the 
initial phase of the release profile may have 
resulted from VCR molecules adsorbed to PEG 
moieties on the vesicle surface [16]. 
 
The pegylated niosomal nanoparticles were 
capable of potentiating the cytotoxic effects of 
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VCR. The increase in cytotoxicity indicated a 
sustained VCR release from nanoparticles, 
resulting from increased penetration of pegylated 
niosomal VCR into cells, compared with the 
standard drug [17]. Nanoparticles devoid of VCR 
had no cytotoxic effect at the ranges evaluated. 
The flow cytometry results are in agreement with 
the fact that the capsulated formulation delivered 
more of the drug into lymphoma cells and 
induced a greater percentage of cell cycle arrest 




Reverse phase evaporation technique is suitable 
for preparing pegylated niosomal VCR 
nanoparticles. Spherical nanoscale ULVs had 
smooth surfaces and high entrapment efficiency, 
and were sufficiently stable and more effective 
than standard VCR. Furthermore, they 
significantly increased the cytotoxic effect of VCR 
against lymphoma cell line. This is probably due 
to the interaction between the vesicular carrier 
and lymphoma cancer cells, causing increased 
drug penetration. The findings also showed that 
pegylated niosome is an appropriate carrier for 
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